Zenith Drugs Ltd
Incorporated in 2000, Zenith Drugs Limited is a pharmaceutical company specializing in manufacturing and trading medicines, including generic drugs.[1]
- Market Cap ₹ 109 Cr.
- Current Price ₹ 63.5
- High / Low ₹ 114 / 52.8
- Stock P/E 33.9
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 23.9 %
- ROE 28.6 %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding has decreased over last quarter: -30.0%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|
| 78.19 | 71.66 | 91.62 | |
| 71.14 | 64.46 | 84.69 | |
| Operating Profit | 7.05 | 7.20 | 6.93 |
| OPM % | 9.02% | 10.05% | 7.56% |
| 0.06 | 0.11 | 0.95 | |
| Interest | 1.31 | 1.49 | 2.14 |
| Depreciation | 0.92 | 1.22 | 1.34 |
| Profit before tax | 4.88 | 4.60 | 4.40 |
| Tax % | 30.12% | 33.26% | 27.05% |
| 3.40 | 3.07 | 3.21 | |
| EPS in Rs | |||
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 29% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|
| Equity Capital | 0.40 | 0.40 | 0.40 |
| Reserves | 6.17 | 9.24 | 12.45 |
| 12.07 | 15.48 | 16.79 | |
| 25.08 | 21.42 | 36.55 | |
| Total Liabilities | 43.72 | 46.54 | 66.19 |
| 6.40 | 9.21 | 10.45 | |
| CWIP | 2.61 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.03 |
| 34.71 | 37.33 | 55.71 | |
| Total Assets | 43.72 | 46.54 | 66.19 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|
| 3.48 | -0.89 | 4.91 | |
| -4.93 | -2.22 | -3.03 | |
| 1.36 | 2.88 | -0.83 | |
| Net Cash Flow | -0.09 | -0.23 | 1.04 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|
| Debtor Days | 118.71 | 119.14 | 127.76 |
| Inventory Days | 29.46 | 52.10 | 66.82 |
| Days Payable | 155.41 | 154.54 | 189.50 |
| Cash Conversion Cycle | -7.24 | 16.69 | 5.09 |
| Working Capital Days | 25.67 | 65.50 | 58.04 |
| ROCE % | 27.83% | 23.89% |
Documents
Announcements
Annual reports
No data available.
Product Portfolio[1]
ORS Powder;
Liquid Orals;
Ointments;
Liquid Externals;
Capsules